Charles M. Farber
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Charles M. Farber

Hematology | Oncology
Atlantic Health
Carol G. Simon Cancer Center
100 Madison Avenue, 
Morristown, NJ 
On Staff At
Accepting New Patients

Experienced in WT1-Related Wilms Tumor Syndromes
Atlantic Health
Carol G. Simon Cancer Center
100 Madison Avenue, 
Morristown, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Charles Farber is a board-certified, fellowship-trained oncologist at Atlantic Hematology Oncology located at Morristown Medical Center’s Carol G. Simon Cancer Center. He maintains a broad-based practice, yet focuses on benign and malignant hematology. Dr. Farber also serves as medical director of Oncology Research Network Development for Atlantic Health System. In this role, he works with the system’s Breakthrough Oncology Accelerator partners, Translational Genomics Research Institute (TGen) and OriginCV, to expand cancer research at Morristown Medical Center and throughout Atlantic Health System. This partnership ensures that patients have access to the newest and most exciting drugs and technologies through clinical trials. In addition to receiving multiple Patient’s Choice Awards, Dr. Farber has been recognized as a Top Doctor in the New York Metro Area, and listed in Inside Jersey magazine’s Top Doctors, and Consumers Research Council’s Guide to America’s Top Oncologists. He is regarded by colleagues and patients as a knowledgeable, compassionate and devoted physician and has been providing expert care to the Morristown community for more than 20 years. Dr. Farber attended New York University School of Medicine for his medical degree and performed his residency and fellowship at Weill Cornell Medical Center. He also earned a master’s degree and PhD from New York University’s Graduate School of Arts and Sciences. Dr. Farber chairs Morristown Medical Center’s cancer subcommittee for adolescents and young adults and serves as secretary and treasurer of the Oncology Society of New Jersey. He was former chief of the division of Hematology/Oncology at Morristown Medical Center from 2007 to 2011. Dr. Farber serves as a clinical assistant professor at Rutgers and at the Cancer Institute of New Jersey. His research has been published in the Journal of the American Nutraceutical Association, the New England Journal of Medicine and the National Cancer Institute’s Clinical Trial Directory.

Dr. Farber is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
New York University School Of Medicine
Residency
Weill Cornell Medical Center
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
Fellowships
Weill Cornell Medical Center
Hospital Affiliations
Atlantic Medical Group
Morristown Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Carol G. Simon Cancer Center
100 Madison Avenue, Morristown, NJ 07960
Call: 973-971-7960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


18 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

27 Total Publications

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results.
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results.
Journal: Blood advances
Published: December 02, 2024
View All 27 Publications
Similar Doctors
Suresh G. Nair
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Suresh G. Nair
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Suresh G. Nair
Hematology | Oncology

LVH Hematology Oncology-1240 Cedar Crest

1240 S Cedar Crest Blvd, Suite 401, 
Allentown, PA 
 (57.4 miles away)
610-402-7880
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philosophy of care | Personalized care starts during my first meeting with a patient and family. That's when I get to know the patient as completely as possible. I want to know about the patient's concerns, values and support system so I can provide care that is specific to him or her. | Also, I am a member of the skin and soft tissue cancer multidisciplinary consultation team. Together we review your diagnostic information and give you a written opinion reflecting the scope of your condition and recommendations for your best course of care. | Why I entered medicine | When I was young, I didn't like seeing doctors. It created a lot of anxiety for me. Now that I'm older, I can relate to the way people feel, especially when they're coping with the emotions caused by a serious condition like cancer. My grandmother died of uterine cancer in the 1960s. During her battle, I felt helpless. That is what attracted me to cancer research. Now I see the amazing progress we are making through cancer research. | Community involvement | I served on the state board of the American Cancer Society. Today, I take more of a grassroots approach to offer my support. I participate in events, such as 5K runs, that benefit charities. Dr. Nair is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Melanoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Rohit K. Jain
Oncology | Hematology Oncology | Hematology

Weill Medical College Of Cornell

1305 York Ave, 
New York, NY 
 (26.8 miles away)
646-962-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohit Jain is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Familial Wilms Tumor 2. Dr. Jain is currently accepting new patients.

Louis R. Kavoussi
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Louis R. Kavoussi
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Louis R. Kavoussi
Oncology

Northwell Health Physician Partners Smith Institute For Urology At Lake Success

450 Lakeville Road, Suite M42, 
Lake Success, NY 
 (40.1 miles away)
516-734-8500
Languages Spoken:
English
See accepted insurances

Louis Kavoussi is an Oncologist in Lake Success, New York. Dr. Kavoussi is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farber's expertise for a condition
ConditionClose
  • Elite
  • Chronic Lymphocytic Leukemia (CLL)
    Dr. Farber is
    Elite
    . Learn about Chronic Lymphocytic Leukemia (CLL).
    See more Chronic Lymphocytic Leukemia (CLL) experts
  • Distinguished
  • Chronic B-Cell Leukemia (CBCL)
    Dr. Farber is
    Distinguished
    . Learn about Chronic B-Cell Leukemia (CBCL).
    See more Chronic B-Cell Leukemia (CBCL) experts
  • Diffuse Large B-Cell Lymphoma (DLBCL)
    Dr. Farber is
    Distinguished
    . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
    See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
  • Follicular Lymphoma
    Dr. Farber is
    Distinguished
    . Learn about Follicular Lymphoma.
    See more Follicular Lymphoma experts
  • Non-Hodgkin Lymphoma
    Dr. Farber is
    Distinguished
    . Learn about Non-Hodgkin Lymphoma.
    See more Non-Hodgkin Lymphoma experts
  • Advanced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Farber is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Mountain Sickness
    Dr. Farber is
    Advanced
    . Learn about Acute Mountain Sickness.
    See more Acute Mountain Sickness experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Farber is
    Advanced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Farber is
    Advanced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • B-Cell Lymphoma
    Dr. Farber is
    Advanced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Classical Hodgkin Lymphoma
    Dr. Farber is
    Advanced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
View All 27 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Farber is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Adult Soft Tissue Sarcoma
    Dr. Farber is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Farber is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Farber is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Anaplastic Large Cell Lymphoma
    Dr. Farber is
    Experienced
    . Learn about Anaplastic Large Cell Lymphoma.
    See more Anaplastic Large Cell Lymphoma experts
  • Anemia
    Dr. Farber is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
View All 84 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved